Engineered NKG2C <sup>+</sup> NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome
Kyle B. Lupo(Purdue University West Lafayette), Katharine C. Hsu(Memorial Sloan Kettering Cancer Center)
Cited by 2
Related Papers
Fasting reshapes tissue-specific niches to improve NK cell-mediated anti-tumor immunity
|Immunity|2024|65
NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand
|The Journal of Immunology|2013|63
synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
|Nature Communications|2024|39